Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Claritas Pharmaceuticals, Inc. (V.CLA) had Consolidated Net Income/Loss of -2.42M for the most recently reported fiscal quarter, ending 2018-03-31.
| Income Statement Financials | |
-- |
|
-2.42M |
|
-- |
|
-- |
|
-- |
|
-2.64M |
|
-- |
|
-2.42M |
|
-2.42M |
|
-2.42M |
|
-2.42M |
|
|
Consolidated Net Income/Loss |
-2.42M |
-2.42M |
|
-2.64M |
|
2.66M |
|
6.55M |
|
6.55M |
|
-0.26 |
|
-0.26 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
80.24M |
|
-- |
|
-- |
|
-- |
|
96.22M |
|
-15.98M |
|
-93.74M |
|
-15.98M |
|
6.66M |
|
| Cash Flow Statement Financials | |
-1.66M |
|
-- |
|
-0.63M |
|
4.66M |
|
2.37M |
|
-2.30M |
|
0.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.35 |
|
-- |
|
-- |
|
5.43 |
|
-1.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1.66M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
15.16% |
|
2.59% |
|
-3.02% |
|
-67.13% |
|
-2.40 |
|
-0.25 |
|
-0.25 |
|